KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.
The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.
We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.
Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:
- Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
- Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
- Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies
KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.
The KMT MouseTM is your essential tool for therapeutics and vaccine development.
October 16 2017
Discuss with KMT Hepatech representative in Berlin, Germany on November 6-8
September 11 2017
KMT Hepatech is honored to participate in the largest European event in toxicity in Bratislava
August 27 2017
Meet Dr. Sapelnikova in Washington, DC at this annual event coordinated by Hepatitis B Foundation